Radiotherapy - Cerebrovascular Reactivity (RT-CVR Study)
MRI Changes With Administered Oxygen and Carbon Dioxide in Patients With Brain Tumors Receiving Radiotherapy: A Pilot Study
1 other identifier
interventional
14
1 country
1
Brief Summary
Brain tumours often have low oxygen levels, and that makes them more resistant to radiation therapy. If patients breathe the right mixture of oxygen during treatment, radiation may work better. In this study, patients with brain tumour will undergo a special MRI test while they breathe different mixtures of oxygen and carbon dioxide to find out whether oxygen levels improve in the tumor. Patients will also be asked to repeat this MRI test during the second week of radiation therapy, as well as 3 months, 6 months and 1 year after RT. The MRI test after RT will help us understand how the blood vessels in the normal brain are affected by radiation.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for phase_2
Started Feb 2005
Longer than P75 for phase_2
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
February 1, 2005
CompletedFirst Submitted
Initial submission to the registry
February 23, 2006
CompletedFirst Posted
Study publicly available on registry
February 27, 2006
CompletedPrimary Completion
Last participant's last visit for primary outcome
May 1, 2013
CompletedStudy Completion
Last participant's last visit for all outcomes
May 1, 2013
CompletedJanuary 6, 2014
January 1, 2014
8.2 years
February 23, 2006
January 3, 2014
Conditions
Outcome Measures
Primary Outcomes (1)
- To measure the inter-patient variability of change in tumour oxygenation with carbogen adminstration using MRI
2 years
Secondary Outcomes (4)
- To determine whether modulation of oxygen and carbon dioxide administration can improve tumour oxygenation relative to standard carbogen breathing on MRI
2 years
- To determine whether changes in tumour oxygenation with carbogen administration are different during the second week of radiotherapy compared to baseline measurements
2 years
- To determine whether the normal brain cerebrovascular reactivity (CVR) measured with MRI changes through a course of radiotherapy and follow-up
2 years
- To determine whether CVR differs between radiation exposed and non-exposed normal brain tissue in a given patient after radiotherapy
2 years
Study Arms (1)
MRI for brain mets
EXPERIMENTALInterventions
Patients will be scanned while breathing in varying amounts of oxygen and carbon dioxide in varying amounts through a breathing device.
Eligibility Criteria
You may qualify if:
- Patients with primary gliomas visible on MRI who are planning to receive radiotherapy or
- Patients with brain metastases\>1cm who are planning to receive radiotherapy
- Karnofsky Performance Status \>60
- Age 18 years
- Patients must be willing to visit Toronto Western Hospital for at least one MRI scan prior radiotherapy
You may not qualify if:
- Seizures not controlled with medications, or non compliance with prescribed anti-seizure medication
- Prior radiation therapy to the brain
- Pregnancy
- Unwilling or unable to co-operate with breathing maneuvers
- Respiratory or cardiac limitations to breathing at 20 L/min
- Medical contra-indications to limited hypercapnia or hypocapnia (known increased intracerebral pressure, metabolic acidosis or alkalosis)
- Contraindication to MRI (patients weighing\>136 kgs-weight limit for the scanner tables; allergy to MR contrast agent; patients with pacemakers, cerebral aneurysm clips, shrapnel injury or implantable electronic devices not compatible with MRI)
- Other medical conditions deemed by the PI or associates to make the patients ineligible for protocol procedures
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
University Health Network
Toronto, Ontario, M5G 2M9, Canada
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Cynthia Ménard, MD
Princess Margaret Hospital, Canada
Study Design
- Study Type
- interventional
- Phase
- phase 2
- Allocation
- NA
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
February 23, 2006
First Posted
February 27, 2006
Study Start
February 1, 2005
Primary Completion
May 1, 2013
Study Completion
May 1, 2013
Last Updated
January 6, 2014
Record last verified: 2014-01